News
ATRA
0.6933
-2.35%
-0.0167
Atara Biotherapeutics Submits Tabelecleucel BLA For Treatment Of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease With U.S. FDA; Acceptance Of BLA Will Trigger $20M Milestone Payment From Pierre Fabre Laboratories, With Potential For Additional $60M Milestone Upon FDA Approval
First Allogeneic T-Cell Therapy BLA Submission to Food and Drug Administration. Tab-cel would be First Approved Therapy in EBV+ PTLD for solid organ transplant patients. Acceptance of BLA will trigger $20 million milestone payment from Pierre Fabre.
Benzinga · 1d ago
ATARA ELIGIBLE FOR ADDITIONAL $60M UPON FDA APPROVAL
Reuters · 1d ago
Weekly Report: what happened at ATRA last week (0513-0517)?
Weekly Report · 1d ago
Atara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA
Atara Biotherapeutics, Inc. Has submitted a Biologics License Application to the FDA for tabelecleucel. Tab-cel is an allogeneic Epstein-Barr virus (EBV) T-cell immunotherapy for patients with EBV positive post-transplant lymphoproliferative disease. Atara is the first company in the world to receive regulatory approval for a T- cell immunotherapy. The company announced the closing of the expanded global partnership with Pierre Fabre.
Barchart · 1d ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Deciphera Pharmaceuticals (DCPH), Atara Biotherapeutics (ATRA) and Nkarta (NKTX)
TipRanks · 6d ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Cytek Biosciences (CTKB), Elanco Animal Health (ELAN) and Atara Biotherapeutics (ATRA)
TipRanks · 05/14 17:20
New Forecasts: Here's What Analysts Think The Future Holds For Atara Biotherapeutics, Inc. (NASDAQ:ATRA)
Analysts have upgraded their revenue forecasts for Atara Biotherapeutics, Inc. (NASDAQ:ATRA) to US$115m in 2024. The consensus estimate is a 230% increase on the company's sales over the past 12 months. The company is expected to grow its revenue much faster than the wider market. Now could be the right time to take a look at the company.
Simply Wall St · 05/14 10:04
Weekly Report: what happened at ATRA last week (0506-0510)?
Weekly Report · 05/13 09:09
Revenues Working Against Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Share Price Following 26% Dive
Atara Biotherapeutics, Inc. Shares are down a considerable 26% in the last month. The company's price-to-sales ratio is low compared to the wider Biotechs industry. Atara's declining revenue growth is contributing to the company's low P/S ratio. Its revenue growth forecast for the next three years is significantly lower than the broader industry.
Simply Wall St · 05/11 12:35
Atara Biotherapeutics, Inc. Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period Ended March 31, 2024
Press release · 05/10 16:46
Buy Rating Affirmed for Atara Biotherapeutics on Strong Pipeline and Financial Health
TipRanks · 05/10 12:15
ATRA Stock Earnings: Atara Biotherapeutics Beats EPS, Beats Revenue for Q1 2024
Atara Biotherapeutics reported results for the first quarter of 2024. The company reported earnings per share of -23 cents and revenue of $27.36 million. This was 10.80% better than the analyst estimate of -26 cents for the quarter.
Investorplace · 05/10 02:57
Atara Biotherapeutics GAAP EPS of -$0.23 beats by $0.02, revenue of $27.36M beats by $2.67M
Earnings News Atara Biotherapeutics GAAP EPS of -$0.23 beats by $0.02, revenue of $27.36M beats by $2.67M. Atara's Q1 GAAP revenue of   was $28.2 million.
Seeking Alpha · 05/09 21:26
Atara Biotherapeutics (ATRA) Reports Q1 Loss, Tops Revenue Estimates
NASDAQ · 05/09 21:15
Atara Biotherapeutics Inc reports results for the quarter ended in March - Earnings Summary
Atara Biotherapeutics Inc reports results for the quarter ended in March. The company reported a quarterly adjusted loss of 23 cents per share. Revenue rose 2,131.4% to $27.36 million from a year ago. Atara shares had fallen by 18.5% this quarter and gained 10.3% this year.
Reuters · 05/09 20:48
Atara Biotherapeutics Q1 2024 GAAP EPS $(0.23) Beats $(0.25) Estimate
Benzinga · 05/09 20:46
*Atara Biotherapeutics 1Q Rev $27.4M >ATRA
Dow Jones · 05/09 20:10
BRIEF-Atara Biotherapeutics Q1 EPS USD -0.23
Reuters · 05/09 20:01
ATARA BIOTHERAPEUTICS INC - CASH RUNWAY INTO 2027 ENABLES KEY PIPELINE READOUTS
Reuters · 05/09 20:01
Press Release: Atara Biotherapeutics Announces -2-
Atara expects to reduce its headcount by approximately 25% to 170 employees. The company says it expects to be able to fund operations into 2027. Atara is developing a CAR-T cell therapy for the treatment of Epstein-Barr virus. It says the company has a potential to be a major player in the field of stem cell therapy.
Dow Jones · 05/09 20:01
More
Webull provides a variety of real-time ATRA stock news. You can receive the latest news about Atara Biotherape through multiple platforms. This information may help you make smarter investment decisions.
About ATRA
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 is in Phase 1 development is being developed as a potential product intended to target B-cell malignancies and autoimmune diseases, based on a next generation 1XX co-stimulatory domain and the innate advantages of EBV T cells as the foundation for an allogeneic CAR T platform.